| Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies N D’souza, F Rossignoli, G Golinelli, G Grisendi, C Spano, O Candini, ... BMC medicine 13, 1-15, 2015 | 172 | 2015 |
| Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood F Rossignoli, A Caselli, G Grisendi, S Piccinno, JS Burns, A Murgia, ... BioMed research international 2013 (1), 901821, 2013 | 113 | 2013 |
| Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors G Golinelli, G Grisendi, M Prapa, M Bestagno, C Spano, F Rossignoli, ... Cancer gene therapy 27 (7), 558-570, 2020 | 91 | 2020 |
| Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, ... Scientific reports 9 (1), 1788, 2019 | 66 | 2019 |
| Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas G Grisendi, C Spano, N D'souza, V Rasini, E Veronesi, M Prapa, ... Stem Cells 33 (3), 859-869, 2015 | 63 | 2015 |
| Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm N Song, H Wakimoto, F Rossignoli, D Bhere, R Ciccocioppo, KS Chen, ... Stem Cells 39 (6), 707-722, 2021 | 60 | 2021 |
| Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy F Rossignoli, G Grisendi, C Spano, G Golinelli, A Recchia, G Rovesti, ... Cancer Gene Therapy 26 (1), 11-16, 2019 | 56 | 2019 |
| MSC-delivered soluble TRAIL and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma F Rossignoli, C Spano, G Grisendi, EM Foppiani, G Golinelli, I Mastrolia, ... Theranostics 9 (2), 436, 2019 | 54 | 2019 |
| Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity KS Chen, C Reinshagen, TA Van Schaik, F Rossignoli, P Borges, ... Science Translational Medicine 15 (677), eabo4778, 2023 | 27 | 2023 |
| Tumor stroma manipulation by MSC G Grisendi, C Spano, F Rossignoli, N Dsouza, G Golinelli, A Fiori, ... Current drug targets 17 (10), 1111-1126, 2016 | 15 | 2016 |
| NK cells in the brain: implications for brain tumor development and therapy A Balatsoukas, F Rossignoli, K Shah Trends in molecular medicine 28 (3), 194-209, 2022 | 14 | 2022 |
| Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma G Golinelli, G Grisendi, M Dall'Ora, G Casari, C Spano, R Talami, ... Translational Oncology 15 (1), 101240, 2022 | 14 | 2022 |
| Human Herpes simplex 1 virus infection of endometrial decidual tissue-derived MSC alters HLA-G expression and immunosuppressive functions D Bortolotti, F Rossignoli, A Rotola, D Campioni, R Cultrera, G Grisendi, ... Human Immunology 79 (11), 800-808, 2018 | 13 | 2018 |
| Soluble TRAIL-Armed Human AD-MSC as Novel Cell Therapy: Approach for Pancreatic Ductal Adenocarcinoma C Spano, G Grisendi, O Candini, G Golinelli, T Petrachi, F Rossignoli, ... Cytotherapy 18 (6), S24-S25, 2016 | 3 | 2016 |
| Developing and characterizing a two-layered safety switch for cell therapies F Rossignoli, D Hoffman, E Atif, K Shah Cancer Biology & Therapy 24 (1), 2232146, 2023 | 2 | 2023 |
| Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice L Liu, TA van Schaik, KS Chen, F Rossignoli, P Borges, V Vrbanac, ... Frontiers in Immunology 14, 1324618, 2024 | 1 | 2024 |
| Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment I Vogiatzi, LM Lama, A Lehmann, F Rossignoli, J Gettemans, K Shah Cytotherapy, 2024 | | 2024 |
| A dual-function inducible immunogenic cell death safety switch for enhanced cancer cell-based immunotherapy KSI Chen, S Manoury-Battais, N Kanaya, I Vogiatzi, P Borges, S Kruize, ... Journal of Clinical Investigation, 2024 | | 2024 |
| An off-the-shelf Twin BiTE combination therapy controls heterogenous glioblastoma and shapes immune response F Rossignoli, P Borges, R Lumia, K Shah Cancer Research 83 (7_Supplement), 6328-6328, 2023 | | 2023 |
| Method to produce conditionally apoptotic cells F Rossignoli, C Spano, G Grisendi, O Candini, M Dominici US Patent App. 17/058,911, 2021 | | 2021 |
